Oncology is the branch of medicine that deals with the study, diagnosis and treatment of cancer and focuses on the management of cancer from diagnosis through to palliative care.
Cancer is a group of cells (usually derived from a single cell) that has lost its normal control mechanisms. Cancerous cells can develop from any tissue within any organ and can spread throughout the body (metastasise). Cancerous tissue can be divided into those of the blood and blood-forming tissue, and solid tumours, carcinomas or sarcomas, or described as breast cancer including metastatic breast cancer, HER2+, triple negative, gynaecological cancers such as ovarian and cervical, and genitourinary cancer such as prostate cancer.
Featured Learning Zones
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Related news and insights
Syndax Pharmaceuticals, Inc. announced receipt of the final results of E2112 the Phase III clinical trial conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute (NCI), that evaluated the investigational compound entinostat, Syndax's class I HDAC inhibitor, plus exemestane in patients with advanced hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) breast cancer who have progressed on a non-steroidal aromatase inhibitor. The trial did not achieve the primary endpoint of demonstrating a statistically significant overall survival (OS) benefit over hormone therapy alone .
Takeda Pharmaceutical announced that the FDA has approved Alunbrig (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending Tecentriq (atezolizumab), from Roche, with chemotherapy drug Abraxane (nab-paclitaxel), for treating patients with metastatic triple negative breast cancer.
The pathogenesis of cancer?associated disseminated intravascular coagulation (DIC) is complex and multifactorial. It could present as a spectrum ranging from clinically asymptomatic, but with laboratory markers of coagulation activation...